Apart from preventing contracting the infection, the nasal spray vaccine will also examine the spread of the infection. As the spray is administered in the nose, it will enter the throat too and avoid proliferation of the infection in both the organs. None of the vaccine candidates being prepared in the entire world will function the method the nasal vaccine does, said medical specialists.
He stated that initially, they had set a target to prepare 1 crore dosages of the vaccine which making the nasal spray vaccine was much easier than the injection-type vaccine. There will be no need of medical consumables like needles and syringes, he mentioned and added that it would also lower the expense of dispersing the vaccine.
The contract will offer rights to Bharat Biotech to provide the intranasal vaccine to all the nations in the world other than US, Japan and Europe.
Attempts are on to distribute the nasal vaccine as a single dosage and this will assist in making the vaccine reach more people quickly, a professor in the Washington University said.
Later on, the pharma giant will start production on a massive. Bharat Biotech chairman and MD Dr Krishna Ella said that their know-how in manufacturing the vaccine and dispersing the same will assist in taking it closer to the individuals.
The Phase-1 scientific trials of this vaccine will be performed at St. Louis University and after acquiring all the required regulative approvals, the further stages of medical trials will be pursued in India.
Bharat Biotech is currently developing Covaxin, a native vaccine versus Covid-19, in collaboration with ICMR-National Institute of Virology and it remains in the Phase-II human scientific trials.
Hyderabad-based pharma giant, Bharat Biotech, participated in licensing arrangement with the Washington University School of Medicine, in manufacturing the vaccine against Covid-19. The Washington University is making nasal spray vaccine basing on the chimpanzee adenovirus.